BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 - 2026

About this update from Biomark Diagnostics, Inc.

Vancouver, British Columbia--(Newsfile Corp. - July 30, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early cancer detection, today announced a summary of its fiscal year 2025 highlights and key milestones for 2025 - 2026. The Company's annual financial filings are available on the SEDAR+ website at www.sedarplus.ca and on the CSE website at https://thecse.com/ . In a globally challenging funding environment for biotechnology firms, BioMark demonstrated exceptional resilience. The Company successfully secured financing and strengthened investor confidence by completing a CAD $4.26 million private placement. This financing round saw strong participation from North American and European investors, underscoring trust in BioMark's management and its execution strategy. Investor confidence remained high throughout the year, with BioMark's share price maintaining stability and posting modest gains. This performance stands in contrast to the downward trend observed across much of the diagnostics and biotech sectors, highlighting the Company's strategic position and strong fundamentals. "Our team remained focused on disciplined execution, data-driven strategy, and delivering tangible value," said Rashid Bux, BioMark's CEO. "That focus earned us the continued support of investors who recognized the significance of our milestones in a tough market." 2025 Fiscal Year Highlights by Strategic Pillar BioMark's key achievements for the fiscal year are categorized below, showcasing a period of significant progress across its core strategic pillars: Financial Strength Operational and Scientific Progress Lab Certification and Commercial Readiness Publications and Thought Leadership Strategic Collaborations Outlook and Key Milestones for 2025-2026 BioMark remains focused on achieving several key milestones in the coming fiscal year: About BioMark Diagnostics Inc. BioMark Diagnostics Inc. is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. BioMark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology. Further information about BioMark is available under its profile on the SEDAR+ website www.sedarplus.ca and the CSE website https://thecse.com/ . For further information on BioMark, please Contact: Rashid Ahmed Bux President & CEO BioMark Diagnostics Inc. Tel. 604-370-0779 Email: [email protected] Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws. The CSE has not reviewed, approved, or disapproved of the content of this press release. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/260607

View stock analysis, news, and events for Biomark Diagnostics, Inc.